Management Team
J. Kevin Judice, Ph.D.
Chief Executive Officer & Chief Scientific Officer
In addition to setting corporate strategy and building the leadership team as President and CEO, Dr. Judice has also served as the company’s Chief Scientific Officer. In this role, he has been responsible for the overall scientific strategy, research priorities, and portfolio management. Previously, Dr. Judice held positions of increasing responsibility at Genentech and Theravance. As one of the first ten employees at Theravance, he played a key role in defining the company’s scientific strategies and led the team that discovered telavancin, a new antibiotic for the treatment of multidrug-resistant “superbugs”. Dr. Judice graduated magna cum laude with a BS in Chemistry from Texas A&M University. Following that, he received his Ph.D. in Organic Chemistry from UCLA and was an NIH postdoctoral fellow at UC Berkeley. In 2008, Dr. Judice was selected as a Henry Crown Fellow by the Aspen Institute. He is an author and inventor on over two dozen scientific papers and patents.
Chief Financial Officer & VP, Operations
Mr. Doyle joins Achaogen from Genentech, a leading biotech company acquired by Roche in March 2009, where he served as Vice President of Finance and Corporate Planning. Previously, he served as Chief Financial Officer and Senior Vice President of Corporate Development at Renovis (acquired by Evotec AG), a publicly-held biotech company focused on neurological diseases and disorders. Mr. Doyle has also held positions at Tularik (acquired by Amgen) and PricewaterhouseCoopers.
Mr. Doyle received an M.B.A. from the Haas School of Business at the University of California, Berkeley, and a B.S. from Cal Poly, San Luis Obispo.
John F. Hollway
VP, Business Development
Mr. Hollway manages Achaogen's financial and strategic operations, and is responsible for its non-dilutive financing efforts. He was most recently the Vice President of Operations, Strategy & Corporate Development, and Chief Privacy Officer for Acurian, Inc., a clinical services company. There he built the company's clinical data services and had responsibility for the overall management of client projects and the establishment and maintenance of industry-leading data management standards and procedures. Prior to joining Acurian, Mr. Hollway was the General Manager in charge of wireless strategy and product development for Shared Medical Systems Corp, now Siemens Medical Systems (SMS). Prior to his business career, Mr. Hollway was an attorney at Morgan, Lewis & Bockius LLP, where he managed numerous complex civil litigation cases, with special emphasis on contractual disputes and business planning to avoid future litigation.
Mr. Hollway holds a J.D. with honors from the George Washington University Law School, and a B.A. from the University of Pennsylvania.
Heinz E. Moser, Ph.D.
VP, Chemistry
Dr. Moser brings an extensive history in drug discovery and medicinal chemistry to Achaogen. He has held various managerial positions with Ciba and Novartis and prior to joining Achaogen, he was Chief Technical Officer and Vice President of Chemistry at GeneSoft (now Oscient), a biotech company dedicated to antibacterial drug discovery and development.
Dr. Moser received his Ph.D. from the Federal Institute of Technology (ETH) in Zurich and served as a post-doctoral fellow at the California Institute of Technology. He is author of over 30 manuscripts in peer-reviewed journals, co-inventor of 10 published patent applications and recipient of the Ruzicka Award, given annually to the best Swiss chemist under age 40.